Johnson & Johnson (NYSE:JNJ) Shares Bought by Well Done LLC

Well Done LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 6.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,778 shares of the company’s stock after purchasing an additional 731 shares during the period. Well Done LLC’s holdings in Johnson & Johnson were worth $1,640,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Highwater Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth $215,000. Steward Partners Investment Advisory LLC grew its stake in shares of Johnson & Johnson by 25.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 166,191 shares of the company’s stock worth $21,447,000 after buying an additional 33,496 shares in the last quarter. Aries Wealth Management grew its stake in shares of Johnson & Johnson by 0.7% in the 4th quarter. Aries Wealth Management now owns 13,897 shares of the company’s stock worth $1,793,000 after buying an additional 102 shares in the last quarter. BKD Wealth Advisors LLC grew its stake in shares of Johnson & Johnson by 2.2% in the 4th quarter. BKD Wealth Advisors LLC now owns 41,344 shares of the company’s stock worth $5,335,000 after buying an additional 887 shares in the last quarter. Finally, RNC Capital Management LLC grew its stake in shares of Johnson & Johnson by 2.5% in the 4th quarter. RNC Capital Management LLC now owns 235,320 shares of the company’s stock worth $30,368,000 after buying an additional 5,832 shares in the last quarter. 66.82% of the stock is currently owned by institutional investors.

In related news, Director Marillyn A. Hewson acquired 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The stock was bought at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the acquisition, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $419,040. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.23% of the company’s stock.

A number of brokerages have commented on JNJ. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price objective for the company. in a research note on Thursday, July 18th. Wells Fargo & Co restated an “outperform” rating and issued a $157.00 target price (up previously from $152.00) on shares of Johnson & Johnson in a report on Monday, May 6th. Raymond James lowered their target price on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a report on Wednesday, July 17th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 17th. Finally, Barclays started coverage on shares of Johnson & Johnson in a report on Friday, June 21st. They issued a “hold” rating and a $140.00 target price for the company. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $148.56.

Shares of Johnson & Johnson stock traded down $0.55 during trading on Monday, hitting $130.52. The stock had a trading volume of 1,628,690 shares, compared to its average volume of 7,695,500. The company has a fifty day simple moving average of $136.70. The firm has a market capitalization of $345.92 billion, a PE ratio of 15.96, a PEG ratio of 2.22 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.13 and a current ratio of 1.33. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. The firm had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business’s revenue was down 1.3% on a year-over-year basis. During the same quarter last year, the business earned $2.10 EPS. Analysts forecast that Johnson & Johnson will post 8.6 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a dividend of $0.95 per share. The ex-dividend date is Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a yield of 2.91%. Johnson & Johnson’s payout ratio is 46.45%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Insider Trading – What You Need to Know

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.